Feltelius N, Hvatum M, Brandtzaeg P, Knutson L, Hällgren R
Department of Internal Medicine, University Hospital, Uppsala, Sweden.
J Rheumatol. 1994 Nov;21(11):2076-81.
To investigate the intestinal immune system in patients with ankylosing spondylitis (AS) and the influence of sulfasalazine treatment.
Total IgA, secretory IgA and IgM and secretory component were determined in jejunal perfusion fluid in 19 patients with AS before and after 3 months' treatment with sulfasalazine and compared with 18 healthy control subjects. Serum immunoglobulins and inflammatory activity were measured with standard methods and compared with a clinical scoring of disease activity.
Total IgA, secretory IgA, IgM and secretory component were significantly increased in the lavage fluid when compared with healthy controls. Treatment with sulfasalazine normalized these alterations.
Our findings demonstrate that the intestinal immune system is activated in AS and that such activation can be influenced by treatment. This observation supports the idea that antigenic stimulation in the gut is a possible causative event in AS.
研究强直性脊柱炎(AS)患者的肠道免疫系统以及柳氮磺胺吡啶治疗的影响。
测定19例AS患者在接受柳氮磺胺吡啶治疗3个月前后空肠灌洗液中的总IgA、分泌型IgA、IgM和分泌成分,并与18名健康对照者进行比较。采用标准方法测定血清免疫球蛋白和炎症活性,并与疾病活动度的临床评分进行比较。
与健康对照相比,灌洗液中的总IgA、分泌型IgA、IgM和分泌成分显著增加。柳氮磺胺吡啶治疗使这些改变恢复正常。
我们的研究结果表明,AS患者的肠道免疫系统被激活,且这种激活可受治疗影响。这一观察结果支持肠道中的抗原刺激可能是AS发病原因的观点。